Oncolytic Virus Cancer Therapy Pipeline Outlook 2025

Strategic Insights -

The oncolytic virus cancer therapy pipeline landscape is booming, with over 120 active players working to develop more than 125 pipeline therapies for the treatment of cancer. The pipeline is filled with promising oncolytic virus therapies, many of which are in the advanced stages of clinical development. These therapies aim to selectively infect and kill cancer cells, thereby reducing the burden of the disease. The pipeline is expected to continue to grow and mature in the coming years, providing new hope for cancer patients worldwide.

Key Takeaways:

  • Genelux Corporation's Olvi-Vec is a proprietary, non-pathogenic oncolytic vaccinia virus in Phase III development for the treatment of Platinum-Resistant/Refractory Ovarian Cancer, which has shown promising clinical results in over 150 subjects.
  • Candel Therapeutics' CAN-2409 (aglatimagene besadenovec) is an adenovirus-based replication deficient engineered gene construct encoding the thymidine kinase gene, which is in Phase III development for the treatment of Prostrate Cancer.
  • CG Oncology's CG0070 is an investigational oncolytic immunotherapy based on a modified common cold adenovirus backbone, which is in Phase III development for the treatment of Non Muscular Invasive Bladder Cancer.
  • Oncolytics Biotech's Pelareorep is an intravenously delivered immunotherapeutic agent, which is being investigated in Phase III for the treatment of Metastatic Breast Cancer.
  • Oryx GmbH's ParvOryx is an oncolytic parvovirus H1 (H-1PV), which is in Phase II development for the treatment of Pancreatic Cancer.
  • Jiangsu Sinorda Biomedicine's SND005 is a type of oncolytic virus that preferentially infects and kills tumor cells, which has shown promising results in treatment of melanoma with more than 44% of patients benefiting.
  • VCN Biosciences' VCN-01 is a conditionally replicative oncolytic adenovirus expressing PH20 hyaluronidase, which is in Phase I development for the treatment of Pancreatic, Serous Epithelial Ovarian Cancer and Squamous Cell of Head and Neck.
  • DelveInsight's Oncolytic Virus Cancer Therapy pipeline report provides comprehensive insights into the pipeline therapies, companies, and molecules working on the development of Oncolytic Virus Cancer Therapy.
  • The report covers in-depth analysis of collaborations, licensing agreement, and financing details for future advancement of the Oncolytic Virus Cancer Therapy market.
  • Promising pipeline drugs such as Gemcitabine, Valacyclovir, CG0070, Keytruda, atezolizumab, Ipilimumab, TBI-1401(HF10), Bevacizumab, Sorafenib, Pembrolizumab, and Talimogene Laherparepvec are being developed for the treatment of various cancer types.

Statistics:

  • Over 120 active players are working to develop more than 125 pipeline therapies for the treatment of cancer.
  • The pipeline is filled with promising oncolytic virus therapies, many of which are in the advanced stages of clinical development.
  • 44% of patients treated with Jiangsu Sinorda Biomedicine's SND005 showed benefits in melanoma treatment.
  • VCN-01 is being investigated in Phase I for the treatment of Pancreatic, Serous Epithelial Ovarian Cancer and Squamous Cell of Head and Neck.
  • Inactive pipeline products in Oncolytic Virus Cancer Therapy include Senolytic virus derived from HIV, oncolytic viruses using Chimeric antigen receptors (CARs), and another 7-8 products.

Sources:

  • M2 PRESSWIRE-September 2, 2025-
  • DelveInsight's, "Oncolytic Virus Cancer Therapy Pipeline Insight 2025" report
  • Genelux Corporation announcement on August 26, 2025
  • Candel Therapeutics' website
  • CG Oncology's website
  • Oncolytics Biotech's website
  • Oryx GmbH's website
  • Jiangsu Sinorda Biomedicine's website
  • VCN Biosciences' website
  • DelveInsight's Oncolytic Virus Cancer Therapy pipeline report
  • M2 Communications
  • M2 PressWIRE